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High Levels of DEK Autoantibodies in Sera of Patients With
Polyarticular Juvenile Idiopathic Arthritis and With Early
Disease Flares Following Cessation of Anti–Tumor
Necrosis Factor Therapy
Nirit Mor-Vaknin,1 Miguel Rivas ,1 Maureen Legendre,1 Smriti Mohan,1 Ye Yuanfan,1
Theresa Mau,1 Anne Johnson,2 Bin Huang,3 Lili Zhao,1 Yukiko Kimura,4 Steven J. Spalding,5
Paula W. Morris,6 Beth S. Gottlieb,7 Karen Onel,4 Judyann C. Olson,8 Barbara S. Edelheit,9
Michael Shishov,10 Lawrence K. Jung,11 Elaine A. Cassidy,12 Sampath Prahalad,13
Murray H. Passo,14 Timothy Beukelman,15 Jay Mehta,16 Edward H. Giannini,2
Barbara S. Adams,1 Daniel J. Lovell,2 and David M. Markovitz1
Objective. The nuclear oncoprotein DEK is an
autoantigen associated with juvenile idiopathic arthritis
(JIA), especially the oligoarticular subtype. DEK is a
secreted chemotactic factor. Abundant levels of DEK and
DEK autoantibodies are found in inflamed synovium in
JIA. We undertook this study to further characterize the
nature of DEK autoantibodies in screening serum samples from 2 different cohorts that consisted mostly of
patients with JIA.
Methods. DEK autoantibody levels were analyzed
in sera from 33 JIA patients, 13 patients with other
inflammatory conditions, and 11 healthy controls, as well
as in 89 serum samples from JIA patients receiving anti–

tumor necrosis factor (anti-TNF) therapy. Recombinant
His-tagged full-length DEK protein (1–375 amino acids
[aa]) and the 187–375-aa and 1–350-aa His-tagged DEK
fragments made in a baculovirus system were used for
enzyme-linked immunosorbent assay (ELISA) and
immunoblotting. The C-terminal 25-aa fragment of DEK
was expressed in a glutathione S-transferase–tagged vector. ELISA results were calculated as area under the
curve by the trapezoidal rule.
Results. DEK autoantibody levels were significantly
higher in patients with polyarticular JIA than in those with
oligoarticular JIA, and were higher in patients with polyarticular JIA who had more active disease after cessation of
anti-TNF therapy. Immunoblotting against the C-terminal
25-aa fragment of DEK confirmed that this section of the
DEK molecule is the most immunogenic domain.
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Conclusion. DEK autoantibody levels are higher in
patients with polyarticular JIA than in those with oligoarticular JIA, and higher in patients who have disease flares
after cessation of anti-TNF therapy. The C-terminal 25-aa
fragment is the most immunogenic portion of DEK. These
findings are significant with respect to the nature of DEK
autoantibodies, their contribution to JIA pathogenesis,
and their implications for JIA management.
Juvenile idiopathic arthritis (JIA) is a chronic
inflammatory condition that includes a group of heterogeneous autoimmune diseases affecting children under
the age of 16 years. It is the most common rheumatic
condition in children and may lead to short- or long-term
disability. Subtypes of JIA include oligoarticular arthritis
(involving ≤4 joints), polyarticular arthritis (involving ≥5
joints, rheumatoid factor [RF] positivity or negativity),
systemic-onset arthritis, enthesitis-related arthritis, psoriatic arthritis, and undifferentiated arthritis (1,2). While
the pathogenesis of JIA is unknown, discovery of DEK
autoantibodies in serum of JIA patients as well as DEK
protein and DEK autoantibodies in synovial fluid of JIA
patients has sparked investigation of DEK’s potential
contribution to the pathogenesis of JIA (3–6).
DEK is a nuclear phosphoprotein that was initially
characterized as part of the dek-can fusion oncogene
resulting from a (6;9) translocation in a subset of patients
with acute myelogenous leukemia (7,8). DEK is involved
in various pathways, including transcriptional regulation,
modulation of chromatin architecture, DNA replication,
and messenger RNA processing (9–11). DEK can also be
secreted and may play a role as an extracellular inflammatory cytokine (12,13).
Autoantibodies to DEK are detectable not only
in the serum of patients with JIA, but also in serum of
patients with granulomatous diseases (e.g., sarcoidosis,
tuberculosis) and several autoimmune diseases, including
systemic lupus erythematosus (SLE), scleroderma, and
idiopathic uveitis. Thus, DEK autoantibodies are associated with clinical conditions characterized by abnormal
immune activation (4,6,14). In view of the limited understanding of JIA, the mechanism by which DEK autoantibodies develop, their specificity, and their contribution
to the pathogenesis of JIA are of great interest.
Because nonspecific autoantibodies are not generally characteristic of JIA, the presence of DEK autoantibodies in JIA is particularly intriguing. DEK and DEK
autoantibodies contribute directly to joint inflammation via
the generation of immune complexes, and acetylation of
the DEK protein enhances its immunogenicity (3). In addition, DEK protein can be secreted by monocytes and
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released by apoptotic T cells acting as an extracellular
chemoattractant, which suggests that DEK is a proinflammatory factor recruiting inflammatory cells to the synovium
(12,13). We recently found that DEK also contributes
directly to the formation of neutrophil extracellular traps
(NETs) (15). NETs are chromatin structures that are
released by activated neutrophils in response to inflammation in order to clear bacteria or fungal infection (16,17).
An excess of NETs can contribute to chronic inflammatory conditions such as rheumatoid arthritis or SLE (18).
Indeed, synovial neutrophils from JIA patients spontaneously generate NETs containing DEK that is recognized
by DEK autoantibodies purified from the synovial fluid of
JIA patients (15). DEK autoantibodies from the synovial
fluid of JIA patients have been found to predominantly
recognize the C-terminus of DEK (3).
Thus, we hypothesized that anti-DEK antibodies
and DEK protein form immune complexes by recognition of the C-terminal portion of the DEK protein, further augmenting the inflammatory process in the joint.
In this study we also show that anti-DEK antibodies
are found at a particularly high level in patients with
polyarticular JIA. These levels are higher than those in
patients with oligoarticular JIA, in whom anti-DEK
antibody levels were previously thought to be highest.
The treatment of JIA has recently been improved
by biologic response modifiers such as anti–tumor necrosis factor (anti-TNF) therapy (19–21). However, anti-TNF
therapy is associated with significant adverse events, including infections (22–24) and a possible increased risk of
cancer (25). Its long-term effects on children are uncertain, and biologic agents are very expensive. Thus, it is
important to ascertain when one can safely discontinue
anti-TNF therapy in children with disease in clinical
remission without significant risk of relapse. Having ascertained that patients with polyarticular JIA have high titers
of anti-DEK antibodies, we measured anti-DEK autoantibody levels in serum samples from patients with polyarticular JIA who participated in a multicenter trial designed
to enable better understanding of when anti-TNF therapy
could be safely stopped. We found significantly higher
levels of DEK autoantibodies upon flare after cessation
of anti-TNF therapy. Further, we determined that the
C-terminal 25–amino acid (25-aa) sequence is the most
immunogenic portion of DEK in a significant percentage
of JIA patient sera.
PATIENTS AND METHODS
Patients. Forty-six children (mean age 11.7 years,
mean disease duration 6.2 years) were enrolled by the Pediatric Rheumatology clinic at the University of Michigan.
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These patients had oligoarticular, polyarticular (RF-positive
and RF-negative), systemic-onset, spondyloarthritis, and psoriatic subtypes. Control subjects without JIA included children with chronic pain, fatigue, low-titer antinuclear antibody
(ANA) positivity, scleroderma, SLE, and juvenile dermatomyositis, but without joint involvement (no arthritis). Patient
recruitment was performed under a protocol approved by the
University of Michigan Institutional Review Board (IRB)
(HUM00014692).
In a second patient cohort for a multicenter study aiming
to identify biomarkers to indicate when it is safe to stop anti-TNF
therapy, 137 patients with polyarticular JIA were enrolled (mean
age 11.3 years, mean disease duration 5.0 years). Parent’s/
patient’s consent (assent, if appropriate) was obtained and
screening for eligibility was performed at the participating site at
which the patient was recruited. Each patient’s eligibility was validated via eligibility case report forms sent immediately to the
Pediatric Rheumatology Collaborative Study Group Coordinating Center at Cincinnati Children’s Hospital Medical Center (see
Supplementary Table 1, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40404/
abstract). The Coordinating Center served as the clinical research
organization for this study and oversaw all matters related to regulatory, financial, and clinical affairs, as well as data management, quality assurance, and analysis. The multicenter study was
approved by the IRB at each participating site and was conducted
in compliance with the Declaration of Helsinki Principles for
Human Experimentation.
Study design. The first patient cohort included randomly enrolled patients treated at the Pediatric Rheumatology
clinic at the University of Michigan. Most JIA patients were
treated with methotrexate and nonsteroidal antiinflammatory
drugs (NSAIDs), and several were also treated with TNF inhibitors and other biologic agents. Sera were collected at the time
of enrollment.
In the second group, patients were enrolled at 16 pediatric rheumatology centers, and serum samples were collected
from 137 children with polyarticular JIA who were receiving
anti-TNF therapy, as approved by IRBs (HUM00033009). Therapy was stopped after a minimum of 6 months for patients with
persistent clinically inactive disease. Clinically inactive disease
was defined using the American College of Rheumatology
(ACR) provisional criteria (26). Disease activity was then monitored prospectively for an additional 8 months or until disease
flare. The primary outcome for this study was disease flare using
a variation of the validated criteria, defined as 30% worsening in
≥3 of any of the 6 juvenile rheumatoid arthritis ACR core set
variables (27), with no more than 1 improving by >30% (28).
The 6 core set variables include the physician’s global assessment of disease activity on a 10-cm visual analog scale (VAS),
the parent’s/patient’s assessment of overall well-being on a
10-cm VAS, functional ability measured by the Childhood
Health Assessment Questionnaire (C-HAQ) (29), the number
of joints with active arthritis, the number of joints with limited
range of motion, and an acute-phase reactant (the erythrocyte
sedimentation rate [ESR]).
Because enrolled subjects began the second phase with
clinically inactive disease, a 30% worsening could represent a
less than clinically important change. Thus, for this study the
patient was considered to have had a disease flare if their disease worsened by 30% and by at least the following amounts:
increases of at least 2 units on a 21-numbered circle VAS (30)
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for the physician’s assessment and parent’s/patient’s assessment, increases of at least 2 joints with active arthritis and at
least 2 joints with limited range of motion, a minimum increase
of 0.125 on the C-HAQ score, and an increase in the ESR from
normal to abnormal.
Laboratory assessment. Whole blood samples were obtained from patients seen in the Pediatric Rheumatology clinic
at the University of Michigan under a protocol approved by the
IRB. Serum in a standard vacutainer blood collection tube was
prepared by allowing the blood sample to clot at room temperature for 15–30 minutes followed by centrifugation at 1,000–
2,000g for 10 minutes. For patients in the anti-TNF study, an
additional 8.5-cc P100 tube to collect plasma was used for antiDEK antibody analysis of all subjects weighing >20 kg at visits
1, 2, and 3 and at disease flare/end of the study. Samples were
processed as described above, stored, and shipped to the
University of Michigan.
Enzyme-linked immunosorbent assay (ELISA).
Microtiter plates were coated with full-length (1–375-aa) or
1–350-aa recombinant DEK (50 ll of 125 ng/well) and incubated overnight at 21°C. Plates were blocked with phosphate
buffered saline plus 0.25% bovine serum albumin and 0.05%
Tween 20 for 30 minutes at room temperature, followed by 3
washes with double-distilled water, 10 minutes of blocking,
and 3 additional washes. Serum samples from JIA patients
and controls (dilutions of 1:200, 1:400, 1:800, 1:1,600, and
1:3,200 in blocking buffer) were added to the plates for 2
hours at room temperature, followed by 3 washes, 10 minutes
of blocking, and 3 additional washes. Biotinylated goat antihuman secondary antibody (Jackson ImmunoResearch) at a
concentration of 1:200,000 in dilution buffer (50 ll/well) was
added for 2 hours of incubation at room temperature, followed by 3 washes and 10 minutes of blocking and washing.
Streptavidin (1:300 in dilution buffer; 50 ll/well) was added
for 1 hour of incubation at room temperature, followed by 5
washes. We added 3,30 ,5,50 -tetramethylbenzidine substrate (50
ll/well) to develop the plate for 5–15 minutes prior to stopping the reaction with 1N H2SO4 (50 ll/well). The optical
density (OD) at 450 nm was read within 20 minutes.
Statistical analysis of ELISA results. Anti-DEK antibody levels in sera from JIA patients, measured at 5 different
dilutions (1:200, 1:400, 1:800, 1:1,600, and 1:3,200), were compared to those in sera from non-JIA patients and healthy controls and expressed as fold change over those in healthy controls
in each individual experiment. Fold changes were calculated by
OD. Results were also plotted as the area under the dilution
curve (AUDC) of each sample, calculated using the trapezoidal
rule. Analysis of variance models were used to compare AUDC
between groups of patients. Statistical significance was defined
as a 2-sided P value of less than 0.05. Receiver operating characteristic (ROC) curve analysis was used to assess the ability of the
AUDC to discriminate among groups. Area under the ROC
curve (AUC) was calculated, as was its 95% confidence interval
(95% CI). The marker showed good discrimination ability if the
interval’s lower limit was >0.5.
To analyze samples from patients participating in the
TNF inhibition study at different time points, we took additional
steps to normalize across the different assays using anti-DEK
monoclonal antibody (BD Biosciences) as a reference. The antiDEK AUC values in JIA patients were standardized against
those in healthy controls. We analyzed the difference in the
AUDC values. Student’s t-test was used to compare patients

DEK AUTOANTIBODY LEVELS IN JIA

597

who had disease flares and those who did not by the 8-month
follow-up visit after discontinuation of anti-TNF therapy.
Cloning and expression of the C-terminal 25-aa domain
of DEK. Expression and purification of His-tagged full-length
DEK and of the 187–375-aa and 1–350-aa His-tagged DEK fragments was performed as described previously (31,32). The Cterminal 25-aa portion of the human DEK protein was amplified
from the His-tagged full-length DEK vector via polymerase
chain reaction (PCR) using primers containing 50 Eco RI and 30
Xho I restriction sites. The PCR product was identified and
eluted from an agarose gel prior to digestion with Eco RI and
Xho I. The pGEX-4T1 vector containing glutathione S-transferase (GST) was also digested with Eco RI and Xho I, and the 25aa DEK fragment was ligated into the pGEX vector. DNA from
clones containing the correct sequence was used to express the
protein in the GST-tagged vector.
Immunoblotting. DEK-specific polyclonal antibodies
were purified as described (32). Protein aliquots (3.5 lg) were
Table 1.

separated by 4–20% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and transferred to a nitrocellulose membrane. The membrane was probed with a 1:400 dilution of
patient sera or a 1:1,000 dilution of rabbit anti-DEK antibody
followed by a horseradish peroxidase–conjugated secondary
goat anti-human antibody or goat anti-rabbit antibody and
detected by enhanced chemiluminescence (Amersham Pharmacia Biotech).

RESULTS
Association of high levels of DEK autoantibodies
with JIA. Previous studies had shown elevated titers of
anti-DEK antibodies in JIA patients, especially those
with oligoarticular disease (4,14). We collected 57 serum
samples from 11 healthy control individuals (the basis

Demographic information on the pediatric patients recruited into both studies*
University of Michigan cohort

Age, mean  SD years
Male:female ratio
Duration of disease, mean  SD years
Diagnosis
Oligoarticular JIA
Extended oligoarticular JIA
RF-positive polyarticular JIA (RA)
RF-negative polyarticular JIA
Systemic-onset JIA
Psoriatic arthritis
Spondyloarthritis
Undifferentiated arthritis
UCTD
SLE
Juvenile DM
MCTD
Localized scleroderma
Other (Kawasaki disease and pericarditis, all ANA positive)
Uveitis
ANA positive
Active arthritis
Current medications
Methotrexate
Glucocorticoids
Hydroxychloroquine
NSAIDs
Mycophenolate mofetil
Leflunomide
Sulfasalazine
TNF inhibitors
Infliximab
Adalimumab
Etanercept
Other biologic agents (anakinra)
Cyclosporine
IVIG

TNF study†

JIA patients
(n = 33)

Non-JIA patients
(n = 13)

Patients with flares
(n = 39)

Patients without flares
(n = 67)

11.7  3.7
9:24
6.2  4.2

14.0  4.0
5:8
2.6  1.7

11.13  5.05
10:29
6.37  4.55

11.18  4.22
21:46
4.48  3.14

8
1
2
12
3
3
1
3
–
–
–
–
–
–
4 (12)
13 (39)
16 (48)

–
–
–
–
–
–
–
–
1
2
2
2
2
3
1 (8)
8 (62)
1 (8)

–
8
2
36
–
–
–
–
–
–
–
–
–
–
–
22 (20)
–

–
9
7
59
–
–
–
–
–
–
–
–
–
–
–
31 (29)
–

17 (52)
2 (6)
9 (27)
24 (73)
1 (3)
3 (9)
6 (18)
5 (15)
3
0
2
2 (6)
2 (6)
1 (3)

4 (31)
4 (31)
5 (36)
2 (15)
4 (31)
0 (0)
0 (0)
1 (8)
1
0
0
0 (0)
1 (8)
1 (8)

13 (12)
–
–
–
–
–
–
39 (37)
3
4
32
–
–
–

28 (26)
–
–
–
–
–
–
67 (63)
2
10
55
–
–
–

* Except where indicated otherwise, values are the number or number (%). JIA = juvenile idiopathic arthritis; TNF = tumor necrosis factor;
RF = rheumatoid factor; RA = rheumatoid arthritis; UCTD = undifferentiated connective tissue disease; SLE = systemic lupus erythematosus;
DM = dermatomyositis; MCTD = mixed connective tissue disease; ANA = antinuclear antibody; NSAIDs = nonsteroidal antiinflammatory
drugs; IVIG = intravenous immunoglobulin.
† Percentages were calculated based on the total number of patients (those with and those without disease flares).
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for statistical calculations), 13 non-JIA control patients,
and 33 JIA patients who were enrolled in our study at
the Pediatric Rheumatology Clinic at the University of
Michigan. The mean  SD age of the JIA patients was
11.7  3.7 years, and their mean  SD disease duration
was 6.2  4.2 years. The majority of JIA patients were
female (24 female, 9 male) (Table 1), and among all 12
healthy controls recruited for the study, 5 were female
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and 7 were male (see Supplementary Table 2, http://
onlinelibrary.wiley.com/doi/10.1002/art.40404/abstract). The
distribution of JIA subtypes included 24% with oligoarticular
arthritis, 36% with RF-negative polyarticular arthritis, 9%
with psoriatic arthritis, 9% with systemic-onset JIA, 6% with
RF-positive polyarticular arthritis, and 3% with spondyloarthritis. ANA positivity was noted in 39% of patients.
Twelve percent of patients had uveitis.

Figure 1. High levels of DEK autoantibodies in patients with juvenile idiopathic arthritis (JIA). A, Serum samples from patients with JIA (n =
33), patients with other rheumatic diseases (n = 13), or healthy controls (n = 11) were serially diluted as indicated and tested for anti-DEK antibody levels by enzyme-linked immunosorbent assay (ELISA). Lines represent individual samples. Samples were compared to those from 5 normal
healthy controls. Results shown are the average of 2–8 independent ELISAs. B, Shown are pairwise comparisons, based on area under the dilution
curve (AUDC), among healthy subjects, JIA patients, and non-JIA patients. Data are shown as box plots. Each box represents the 25th to 75th
percentiles. Lines inside the boxes represent the median. Lines outside the boxes represent the 10th and 90th percentiles. Circles indicate outliers.
C, The area under the receiver operating characteristic curve (AUC) was calculated along with its 95% confidence interval (95% CI) to assess the
performance of the AUDC measurements in distinguishing between different groups of patients.

DEK AUTOANTIBODY LEVELS IN JIA

With regard to medications used by patients at the
time of study enrollment and blood sampling, 52% of
patients were being treated with methotrexate, 27% with
hydroxychloroquine, 73% with NSAIDs, 6% with glucocorticoids, 9% with leflunomide, 18% with sulfasalazine,
15% with TNF inhibitors, and 6% with anakinra (primarily for systemic-onset JIA). Of these JIA patients, 53%
had active disease at the time of blood collection.
The mean  SD age of the non-JIA patients with
rheumatic disease at the time of serum collection was
14.0  4.0 years, and their mean  SD disease duration
was 2.6  1.7 years. There was a fairly equal distribution
of other autoimmune diseases in this group, including
relatively equal numbers of patients with SLE, juvenile
dermatomyositis, mixed connective tissue disease, and
localized scleroderma. One patient with idiopathic uveitis who was receiving steroid-sparing agents was also in
this group. The healthy control group was made up of

599

healthy college student volunteers with a mean  SD age
of 20  5 years.
Sera were analyzed by ELISA for anti-DEK antibody levels using recombinant DEK protein. Serum samples were serially diluted and were tested for anti-DEK
antibody levels as described in Patients and Methods. Figure 1A depicts the average results of 2–8 independent
ELISAs. Samples were compared to those from 5 normal
healthy controls. As shown in Figure 1A and Supplementary Figure 1 (http://onlinelibrary.wiley.com/doi/10.1002/
art.40404/abstract), JIA patients had significantly higher
levels of anti-DEK antibodies than did non-JIA patients
and healthy controls. Although there appeared to be
slightly higher levels of anti-DEK antibodies detected by
ELISA among non-JIA patients than among healthy controls, the difference was not statistically significant. Figure 1B demonstrates ELISA antibody titers as pairwise
comparisons based on the AUDC values among healthy

Figure 2. DEK autoantibody levels are significantly higher in patients with polyarticular arthritis (poly) than in those with oligoarticular arthritis
(oligo) or in healthy controls (Healt). DEK autoantibody levels in the sera of patients with different juvenile idiopathic arthritis (JIA) subtypes, as
analyzed by anti-DEK antibody enzyme-linked immunosorbent assay, were compared to those in healthy controls. All levels of antibodies to DEK
were compared to those in sera from healthy individuals based on area under the dilution curve (AUDC). Data are shown as box plots. Each box
represents the 25th to 75th percentiles. Lines inside the boxes represent the median. Diamonds represent the mean. Lines outside the boxes represent the 10th and 90th percentiles. Circles indicate outliers. RA = patients with rheumatoid arthritis; contr = patients seen in the rheumatology
clinic who did not in fact have arthritis; other = patients with no definitive JIA subtype at the time of diagnosis; PsA = patients with psoriatic
arthritis; syste = patients with systemic-onset arthritis. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.
com/doi/10.1002/art.40404/abstract.
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subjects, JIA patients, and non-JIA patients. JIA patients
had a significantly higher AUDC than did either non-JIA
patients (P = 0.03) or healthy controls (P = 0.003). To test
the specificity of our assay, we used the ROC test as shown
in Figure 1C. DEK autoantibody levels showed good discrimination among JIA patients, non-JIA patients, and
healthy subjects, confirming the presence of increased
levels of anti-DEK antibodies in patients with JIA.
Significantly higher DEK autoantibody levels in
patients with polyarticular arthritis than in patients with
oligoarticular arthritis or in healthy individuals. Previous
reports have suggested that anti-DEK antibodies are especially found in JIA patients with the oligoarticular form of
the disease. Therefore, DEK autoantibody levels in sera
from patients with different JIA subtypes were compared
to levels in sera from healthy controls and analyzed by
anti-DEK antibody ELISA (Figure 2). All anti-DEK antibody levels were compared to levels in sera from healthy
individuals and were assessed as AUDC. As shown in Figure 2, there was a statistically significant difference in
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AUDC between healthy controls and patients with polyarticular JIA (P = 0.0011) and between healthy controls
and patients with other forms of JIA (P = 0.0064). No significant differences were found between patients with
oligoarticular JIA and healthy individuals (P = 0.63), but a
significant difference was noted between patients
with oligoarticular JIA and those with polyarticular JIA
(P = 0.0101), with the latter group being statistically more
likely to have higher levels of DEK autoantibodies. High
levels of DEK autoantibodies were also detected in 2
patients with spondyloarthritis and 2 patients with arthritis
as a manifestation of their undifferentiated connective tissue disease (categorized as “other”).
DEK autoantibody levels in patients receiving antiTNF therapy. Anti-TNF therapy has proven to be a very
valuable modality in the treatment of JIA (19–21). However, it is expensive, and its immunosuppressive effects can
lead to opportunistic infections, skin disorders, colitis, and
malignancies (33,34). Further, the long-term effects of antiTNF therapy on children remain unclear (35). Therefore,

Figure 3. Increase in anti-DEK antibodies is evident in patients with juvenile idiopathic arthritis who have disease flares within 8 months of stopping anti–tumor necrosis factor therapy. Top and middle, Shown are data on sera from 89 of 106 patients who were analyzed for anti-DEK antibody
levels. High levels of anti-DEK antibodies (mean  SD difference in area under the dilution curve [AUDC] values [mAUC] 0.164  0.39 [95% confidence interval {95% CI} 0.02, 0.31]) were detected in the 30 patients who had disease flares within 8 months (middle), while lower levels of antiDEK antibodies (mean  SD difference in AUDC values –0.05  0.39 [95% CI –0.15, 0.05]) were detected in the 59 patients who had no disease
flares for at least 8 months and up to 14 months (flare_mo14) (top) (P = 0.016 by Student’s t-test). The difference between the 2 populations is
demonstrated by a normal distribution, and the same trend is shown by a kernel density distribution to demonstrate the distribution of the data
based on the actual spread/density of the results. Bottom, Data are shown as box plots. Each box represents the 25th to 75th percentiles. Lines
inside the boxes represent the median. Diamonds represent the mean. Lines outside the boxes represent the 10th and 90th percentiles. Circles indicate outliers. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40404/abstract.
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strategies are much needed for deciding when to stop treatment after it is initiated. Accordingly, we measured DEK
autoantibodies in a larger cohort of JIA patients who
received anti-TNF therapy (Table 1; also see Supplementary Table 1, http://onlinelibrary.wiley.com/doi/10.1002/art.
40404/abstract). We enrolled 103 female patients and 34
male patients with polyarticular JIA (mean age 11.3 years,
mean disease duration 5.0 years). Seventy-seven percent
were receiving etanercept, 18% were receiving adalimumab, 5% were receiving infliximab, and 40% were
receiving concomitant methotrexate. Thirty-one patients
discontinued the study for various reasons, including reactivation of disease during therapy.
Within 8 months of stopping therapy, 39 patients
had disease flares but 67 patients did not. Anti-DEK antibody levels at the time of stopping anti-TNF therapy did
not differ significantly between these 2 groups of patients
(see Supplementary Figure 2, http://onlinelibrary.wiley.
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com/doi/10.1002/art.40404/abstract). However, at the end
of the study, either after 8 months of no disease flare without therapy or at the time of disease flare without therapy,
high levels of anti-DEK antibodies (mean  SD difference
in AUDC values 0.164  0.39 [95% CI 0.02, 0.31]) were
detected in 30 of the patients who had disease flares, while
lower levels of anti-DEK antibodies (mean  SD difference in AUDC values –0.05  0.39 [95% CI –0.15, 0.05])
were measured in 59 of the patients with no disease flares
(P = 0.016 by Student’s t-test) (Figure 3). Thus, retrospectively, patients who experienced disease flares within 8
months of stopping anti-TNF therapy had significantly
higher levels of anti-DEK antibodies than did patients with
clinically inactive disease until the end of the study.
Requirement of the C-terminal portion of the DEK
protein for autoantibody recognition. Previous studies with
a very limited number of sera and synovial fluid samples
suggested that anti-DEK antibodies target the last 25

Figure 4. Antibodies in sera from patients with juvenile idiopathic arthritis (JIA) recognize the C-terminal domain of the DEK protein. A, Illustration of the different fragments and domains of recombinant histidine-tagged DEK with posttranslational modifications previously identified in
primary human macrophages and HeLa cells (3). B, Results of Western blot analysis of DEK fragments (1 lg protein per lane) expressed in Sf9
cells. DEK protein was probed with serum samples from a normal healthy control subject (NHS), from 3 JIA patients, or from a rheumatology
patient without JIA, or with DEK-specific antibody as a positive control. C, Levels of anti-DEK antibodies. Sera from 4 JIA patients and either
sera or plasma from 4 healthy controls (N1–N4) were serially diluted and tested for antibodies to full-length (1–375–amino-acid) recombinant
DEK (top) or the 1–350–amino-acid DEK fragment (bottom) by enzyme-linked immunosorbent assay (ELISA). Values are the mean  SD fold
change compared to another set of sera from 4 different healthy controls. P = 0.0337 by Student’s t-test for recognition of full-length DEK by sera
from JIA patients versus sera from healthy controls (top). P = 0.009 by Student’s t-test for recognition of full-length DEK by sera from JIA
patients (top) versus recognition of the 1–350–amino-acid DEK fragment by sera from JIA patients (bottom). Color figure can be viewed in the
online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40404/abstract.
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amino acids of the molecule (3). To address this question
further, full-length, 1–350-aa, and 187–375-aa fragments of
recombinant His-tagged DEK were first expressed in Sf9
insect cells. The overlapping fragments were designed to
investigate the immunogenic importance of the C-terminal
portion of DEK, specifically the C-terminal 25 amino acids,
as shown in Figure 4A. DEK protein fragments were then
purified and analyzed by immunoblotting (Figure 4B).
DEK protein was probed with serum samples from a normal healthy control subject, from 3 JIA patients, or from a
rheumatology patient without JIA, or with DEK-specific
antibody as a positive control.
As shown in Figure 4B, the DEK-specific antibody
strongly detected all DEK fragments. The full-length
DEK protein was detected as expected primarily at 55 kd;
a previously identified breakdown form was also detected
at 35 kd (12). (The 1–350-aa DEK runs slightly higher
than the full-length DEK, perhaps due to changes in its 3dimensional structure.) Serum from the normal healthy

MOR-VAKNIN ET AL

control did not notably detect DEK or its fragments. Sera
from all 3 JIA patients readily detected full-length DEK
protein as well as the 187–375-aa fragment, which contains the C-terminal 25 amino acids, consistent with our
previous findings using autoantibodies found in synovial
fluid samples from patients (3). The non-JIA patient sera
detected the full-length and 187–375-aa DEK fragments,
consistent with the observation that patients with other
autoimmune diseases can also have antibodies to DEK.
In contrast, the 1–350-aa DEK fragment lacking only the
last 25 amino acids could not be recognized by most
patient sera (3 of 4 serum samples did not recognize the
truncated fragment). These results are consistent with our
previous findings that 5 of 8 JIA patients’ synovial fluid
antibodies that recognized DEK (>50%) failed to recognize DEK when the C-terminal 25 amino acids were
deleted as in the 1–350-aa DEK mutant (3).
ELISAs were performed to determine further if
autoantibodies in patient sera indeed primarily recognize

Figure 5. The last 25 amino acids (aa) of DEK are sufficient for recognition by the autoantibodies of a substantial percentage of patients with
juvenile idiopathic arthritis (JIA) who have autoantibodies to full-length DEK. A, Recombinant full-length DEK (rDEK), glutathione S-transferase
(GST) control protein, and the C-terminal GST-tagged 25 amino acids of DEK (GST-25aa) were purified and analyzed by Western blotting and
densitometry. Results from 2 different representative JIA patient sera (P03 and P33) are shown in addition to a representative control serum from
a healthy individual. B, Pie chart demonstrates the percentage of patients who had autoantibodies to full-length DEK as detected in sera from
patients with polyarticular JIA (poly), oligoarticular JIA (oligo), psoriatic arthritis (PsA), rheumatoid arthritis (RA), systemic-onset JIA, and nonJIA rheumatic diseases (control) (left). From the 46 patients screened, we also calculated the percentage of patients whose sera recognized the last
25 amino acids of DEK alone, also divided into the different JIA subtypes and non-JIA rheumatic diseases (right). Note that overall, approximately half of the patients’ sera that recognized full-length DEK also recognized the isolated C-terminal 25 amino acids of the protein. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40404/abstract.
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the last 25 amino acids of DEK. Sera from 4 patients with
JIA and either sera or plasma from 4 healthy controls were
serially diluted and tested for antibodies to full-length (1–
375-aa) recombinant DEK or to DEK containing amino
acids 1–350 (the entire DEK protein except for the Cterminal 25 amino acids). DEK was not recognized by sera
from healthy controls, while sera from JIA patients were
able to recognize wild-type DEK (Figure 4C). Although
levels of DEK recognition varied among JIA patients, all
levels of DEK recognition among JIA patients were significantly greater than among healthy controls. This difference disappeared, however, when ELISA was performed
using the 1–350-aa DEK fragment, which was not recognized by sera from JIA patients or controls (Figure 4C).
Antibodies in sera from JIA patients recognize
the last 25 amino acids of the DEK protein. To determine if DEK’s autoantigenicity truly resides in its terminal 25 amino acids, we produced the last 25 amino acids
of DEK with a GST tag. Recombinant full-length DEK,
GST control protein, and the C-terminal GST-tagged 25
amino acids of DEK were purified and analyzed using a
DEK-specific polyclonal antibody, an antibody to GST,
serum from a representative healthy control, and sera
from 3 different JIA patients (Figure 5A).
The serum from the healthy control did not detect
DEK protein, while sera from all of the JIA patients
detected full-length DEK. Sera from 2 representative JIA
patients also detected the GST-tagged 25-aa fragment,
indicating recognition of the C-terminal portion of the
DEK protein but not of the GST control protein. We next
screened all 46 patient samples for recognition of fulllength DEK and the GST-tagged 25-aa DEK fragment
(Figure 5B). Approximately four-fifths (78.3%) of the
sera from JIA patients recognized full-length DEK, but
only half of those sera (one-third of the sera from the
total patient cohort) recognized the C-terminal portion of
DEK. Stated another way, of the patients with antibodies
to full-length DEK, 50% had antibodies that recognized
the C-terminal 25-aa fragment alone. Most of the patients
with autoantibodies recognizing the C-terminus of DEK
had the polyarticular subtype. Therefore, in some but not
all cases, the C-terminal 25-aa DEK fragment can be sufficient to generate DEK autoantibodies. Taken together,
these findings demonstrate that the C-terminal 25 amino
acids are usually necessary, but only sometimes sufficient,
to generate autoantibodies to DEK.
DISCUSSION
DEK, originally identified as a nuclear protein, is
a key factor in the modulation of global chromatin structure (10). In addition to that significant function, the
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DEK protein plays a role in immunity and is also recognized as an autoantigen in JIA and other autoimmune
diseases. Our research group found that DEK binds to a
specific sequence in the Y box of the HLA–DQA1 promoter (36), an allele that predisposes children in northern European populations to the development of
oligoarticular-onset JIA (37,38). We also previously
demonstrated that DEK is actively secreted by human
macrophages and passively released by apoptotic T cells,
attracting leukocytes into the inflamed area (12,13).
DEK and DEK autoantibodies are abundant in synovial
fluid of patients with JIA, leading to the development of
immune complexes in the affected joints (3). Autoantibodies to DEK also show increased affinity for acetylated and poly(ADP-ribosyl)ated DEK (13). We have
also recently shown that DEK is not only secreted by
activated macrophages but is also released by activated
neutrophils, and it was found to be an important component of NETs. Indeed, DEK-knockout mice develop
much less joint inflammation after zymosan injection
due to decreased formation of NETs, and inflammation
in the joints can be reduced by neutralizing DEK with
specific anti-DEK aptamers (15). Thus, DEK and DEK
autoantibodies appear to contribute to joint inflammation by attracting inflammatory cells, generating immune
complexes, and supporting NET formation.
The DEK protein was initially described as an
autoantigen in 1991 by Szer et al (4,5). With the exception
of ANAs, autoantibodies are commonly absent in children
with JIA (14). The discovery of antibodies to the DEK
nuclear antigen in JIA therefore holds promise for
improving our understanding of the pathogenesis and
management of JIA. Reactivity to anti-DEK antibodies
was found to be most strongly associated with onset of
any JIA subtype before the sixth birthday, particularly
early-onset oligoarticular JIA and iridocyclitis. However,
DEK autoantibody levels were previously not found to
have a correlation with disease severity (14). Using
recombinant full-length DEK, we have screened multiple
sera from JIA patients from 2 different cohorts, 46
patients from the Pediatric Rheumatology clinic at the
University of Michigan and 89 patients with polyarticular
JIA receiving anti-TNF therapy from a study coordinated
by the Cincinnati Children’s Hospital Medical Center. In
both patient cohorts, high levels of DEK autoantibodies
were significantly correlated with polyarticular arthritis
(surprisingly, greater than in oligoarticular arthritis) (Figure 2), and higher levels of DEK autoantibodies were
found to be correlated with disease flare within the 8
months after cessation of anti-TNF therapy (P = 0.016)
(Figure 3). These findings show that DEK autoantibody
levels correlate with disease activity and might contribute
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to disease pathogenesis. However, while at this point we
have shown that anti-DEK antibody levels correlate with
active disease, they cannot yet be used to predict whether
it is safe to discontinue anti-TNF therapy.
We have now also demonstrated in a large group
of patients that the C-terminal 25-aa sequence of DEK is
a major autoantigenic region and is sometimes sufficient
to generate an autoimmune response. These findings suggest that more refined ELISAs using the C-terminal 25-aa
sequence of DEK might prove to be of future use. Taken
together, it appears that by understanding the action of
DEK and anti-DEK antibodies, improvements can be
made in the management of JIA.
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